Current understanding of conventional outflow dysfunction in glaucoma

Current Opinion in Ophthalmology

Volumn 23, Issue 2, 2012, Pages 135-143

  Stamer, W Daniel ^a   Acott, Ted S ^b  

^a DUKE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Intraocular pressure; Outflow facility; Schlemm's canal; Trabecular meshwork

Indexed keywords

RHO KINASE INHIBITOR;

AQUEOUS HUMOR OUTFLOW; CHANNEL GATING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

AQUEOUS HUMOR; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

EID: 84857232483     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834ff23e     Document Type: Review

References (108)

1. Grant WM. Clinical tonography. Trans Am Acad Ophthalmol Otolaryngol 1951; 55:774-781.
2. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol 1963; 69:783-801.
3. Bradley JM, Anderssohn AM, Colvis CM, et al. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL1beta and TNFalpha. Invest Ophthalmol Vis Sci 2000; 41:422-430. (Pubitemid 30080445)
4. Latina MA, et al. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology 1998; 105:2082-2088, discussion 2089-2090.
5. Susanna R Jr, Vessani RM, Sakata L, et al. The relation between intraocular pressure peak in the water drinking test and visual field progression in glaucoma. Br J Ophthalmol 2005; 89:1298-1301. (Pubitemid 41638869)
6. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9:134-142. (Pubitemid 32441322)
7. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol 1965; 4:187-197.
8. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965; 4:198-205.
9. Stone EM, Fingert JH, Alward WLM, et al. Identification of a gene that causes primary open angle glaucoma. Science 1997; 275:668-670. (Pubitemid 27061334)
10. Wilkinson C, van der Straaten D, Craig J, et al. Tonography demonstrates reduced facility of outflow of aqueous humor in myocilin mutation carriers. J Glaucoma 2003; 12:237-242. (Pubitemid 36736725)
11. Leydhecker W, Akiyama K, Neumann HG. Intraocular pressure in normal human eyes. Klin Monbl Augenheilkd Augenarztl Fortbild 1958; 133:662-670.
12. Palmberg P. Evidence-based target pressures: how to choose and achieve them. Int Ophthalmol Clin 2004; 44:1-14. (Pubitemid 38509210)
13. Ayyala RS, Zurakowski D, Smith JA, et al. A clinical study of the Ahmed glaucoma valve implant in advanced glaucoma. Ophthalmology 1998; 105:1968-1976. (Pubitemid 28509741)
14. Azuara-Blanco A, Katz LJ. Dysfunctional filtering blebs. Surv Ophthalmol 1998; 43:93-126. (Pubitemid 28460020)
15. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114:1965-1972. (Pubitemid 350016362)
16. Bahler CK, Hann CR, Fautsch MP, Johnson DH. Pharmacological disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes. Invest Ophthalmol Vis Sci 2004; 45:2246-2254. (Pubitemid 38902596)
17. Johnson M, Shapiro A, Ethier CR, Kamm RD. Modulation of outflow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci 1992; 33:1670-1675.
18. Maepa O, Bill A. Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Exp Eye Res 1992; 54:879-883.
19. Overby DR, Stamer WD, Johnson M. The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res 2009; 88:656-670.
20. Gong H, Freddo TF. The washout phenomenon in aqueous outflow -why does it matter? Exp Eye Res 2009; 88:729-737.
21. Lu Z, Overby DR, Scott PA, et al. The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp Eye Res 2008; 86:271-281.
22. Sabanay I, Gabelt BT, Tian B, et al. H-7 effects on the structure and fluid conductance of monkey trabecular meshwork. Archives of Ophthalmology 2000; 118:955-962. (Pubitemid 30460635)
23. Lu Z, Zhang Y, Freddo TF, Gong H. Similar hydrodynamic and morphological changes in the aqueous humor outflow pathway after washout and Y27632 treatment in monkey eyes. Exp Eye Res 2011; 93:397-404.
24. Ethier CR, Chan DW. Cationic ferritin changes outflow facility whereas anionic ferritin does not. Invest Ophthalmol Vis Sci 2001; 42:1795-1802. (Pubitemid 32652355)
25. Johnson M, Chan D, Read AT, et al. The pore density in the inner wall endothelium of Schlemm's canal of glaucomatous eyes. Invest Ophthalmol Vis Sci 2002; 43:2950-2955. (Pubitemid 34977044)
26. Allingham RR, de Kater AW, Ethier CR, et al. The relationship between pore density and outflow facility in human eyes. Invest Ophthalmol Vis Sci 1992; 33:1661-1669.
27. Pedrigi RM, et al. Pores form in cultured Schlemm's canal endothelial cells during transendothelial perfusion. Invest Ophthalmol Vis Sci 2011. ARVO: abstract# 6265.
28. Wan Z, Woodward DF, Stamer WD. Endogenous bioactive lipids and the regulation of conventional outflow facility. Expert Rev Ophthalmol 2008; 3:457-470.
29. Bahler CK, Howell KG, Hann CR, et al. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol 2008; 145:114-119. (Pubitemid 350265755)
30. Millard LH, Woodward DF, Stamer WD. The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. Invest Ophthalmol Vis Sci 2011; 52:3506-3513.
31. Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci 2007; 48:4107-4115. (Pubitemid 351261036)
32. Woodward DF, Nilsson SF, Toris CB, et al. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. Invest Ophthalmol Vis Sci 2009; 50:3320-3328.
33. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008; 53 (Suppl 1):S107-S120.
34. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111:1351-1358. (Pubitemid 23296779)
35. Stamer WD, Piwnica D, Jolas T, et al. Cellular basis for bimatoprost effects on human conventional outflow. Invest Ophthalmol Vis Sci 2010; 51:5176-5181.
36. Njie YF, He F, Qiao Z, Song ZH. Aqueous humor outflow effects of 2-arachidonylglycerol. Exp Eye Res 2008; 87:106-114.
37. Njie YF, Qiao Z, Xiao Z, et al. N-arachidonylethanolamide-induced increase in aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2008; 49:4528-4534.
38. Njie YF, Kumar A, Qiao Z, et al. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2006; 47:1999-2005. (Pubitemid 46768281)
39. Zhong L, Geng L, Njie Y, et al. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2005; 46:1988-1992.
40. Stamer WD, Golightly SF, Hosohata Y, et al. CB1 cannabinoid receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol 2001; 431:277-286. (Pubitemid 33145404)
41. Mettu PS, Deng PF, Misra UK, et al. Role of lysophopholipid growth factors in the modulation of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2004; 45:2263-2271. (Pubitemid 38906709)
42. Stamer WD, Read AT, Sumida GM, Ethier CR. Sphingosine-1-phosphate effects on the inner wall of Schlemm's canal and outflow facility in perfused human eyes. Exp Eye Res 2009; 89:980-988.
43. Sumida GM, Stamer WD. Sphingosine-1-phosphate enhancement of cortical actomyosin organization in cultured human Schlemm's canal endothelial cell monolayers. Invest Ophthalmol Vis Sci 2010; 51:6633-6638.
44. Sumida GM, Stamer WD. S1P2 receptor regulation of sphingosine-1- phosphate effects on conventional outflow physiology. Am J Physiol Cell Physiol 2011; 300:C1164-C1171.
45. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res 1994; 59:723-727.
46. Gottanka J, Chan D, Eichhorn M, et al. Effects of TGF-beta2 in perfused human eyes. Invest Ophthalmol Vis Sci 2004; 45:153-158. (Pubitemid 38055681)
47. Fuchshofer R, Welge-Lussen U, Lutjen-Drecoll E. The effect of TGF-beta2 on human trabecular meshwork extracellular proteolytic system. Exp Eye Res 2003; 77:757-765. (Pubitemid 37373590)
48. Fuchshofer R, Stephan DA, Russell P, Tamm ER. Gene expression profiling of TGFbeta2- and/or BMP7-treated trabecular meshwork cells: identification of Smad7 as a critical inhibitor of TGF-beta2 signaling. Exp Eye Res 2009; 88:1020-1032.
49. Wordinger RJ, Fleenor DL, Hellberg PE, et al. Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest Ophthalmol Vis Sci 2007; 48:1191-1200. (Pubitemid 351261414)
50. Wang WH, McNatt LG, Pang IH, et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest 2008; 118:1056-1064. (Pubitemid 351364613)
51. Li A, Leung CT, Peterson-Yantorno K, et al. Cytoskeletal dependence of adenosine triphosphate release by human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2011; 52:7996-8005.
52. Li A, Leung CT, Peterson-Yantorno K, et al. Mechanisms of ATP release by human trabecular meshwork cells, the enabling step in purinergic regulation of aqueous humor outflow. J Cell Physiol 2011; 227:172-182.
53. Chowdhury UR, Bahler CK, Hann CR, et al. ATP-sensitive potassium (KATP) channel activation decreases intraocular pressure in the anterior chamber of the eye. Invest Ophthalmol Vis Sci 2011; 52:6435-6442.
54. Crosson CE, Sloan CF, Yates PW.Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Invest Ophthalmol Vis Sci 2005; 46:3795-3799 (Pubitemid 44264688)
55. Borghi V, Bastia E, Guzzetta M, et al. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther 2010; 26:125-132.
56. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am J Physiol Cell Physiol 2008; 294:C1378-C1386.
57. Nathanson JA. Nitrovasodilators as a new class of ocular hypotensive agents. J Pharmacol Exp Ther 1992; 260:956-965.
58. Schuman JS, Erickson K, Nathanson JA. Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys. Exp Eye Res 1994; 58:99-105. (Pubitemid 24071624)
59. Stamer WD, et al. eNOS, a pressure-dependent regulator of intraocular pressure. Invest Ophthalmol Vis Sci (in press).
60. Acott TS, Kelley MJ. Extracellular matrix in the trabecular meshwork. Exp Eye Res 2008; 86:543-561.
61. Keller KE, Aga M, Bradley JM, et al. Extracellular matrix turnover and outflow resistance. Exp Eye Res 2001; 676-682.
62. Bradley JM, Kelley MJ, Zhu XH, et al. Effects of mechanical stretching on trabecular matrix metalloproteinases. Invest Ophthalmol Vis Sci 2001; 42:1505-1513. (Pubitemid 32520742)
63. Borras T, Rowlette LL, Tamm ER, et al. Effects of elevated intraocular pressure on outflow facility and TIGR/MYOC expression in perfused human anterior segments. Invest Ophthalmol Vis Sci 2002; 43:33-40. (Pubitemid 34032437)
64. Johnstone MA, Grant WM. Pressure-dependent changes in structures of the aqueous outflow system of human and monkey eyes. Am J Ophthalmol 1973; 75:365-383.
65. Vittal V, Rose A, Gregory KE, et al. Changes in gene expression by trabecular meshwork cells in response to mechanical stretching. Invest Ophthalmol Vis Sci 2005; 46:2857-2868. (Pubitemid 43086708)
66. Vittitow J, Borras T. Genes expressed in the human trabecular meshwork during pressure-induced homeostatic response. J Cell Physiol 2004; 201:126-137. (Pubitemid 39187051)
67. Aga M, Bradley JM, Keller KE, et al. Specialized podosome- or invadopodialike structures (pils) for focal trabecular meshwork extracellular matrix turnover. Invest Ophthalmol Vis Sci 2008; 49:5353-5365.
68. Bradley JM, Kelley MJ, Rose A, Acott TS. Signaling pathways used in trabecular matrix metalloproteinase response to mechanical stretch. Invest Ophthalmol Vis Sci 2003; 44:5174-5181. (Pubitemid 37475386)
69. Borras T. Gene expression in the trabecular meshwork and the influence of intraocular pressure. Prog Retin Eye Res 2003; 22:435-463. (Pubitemid 36556144)
70. Keller KE, Kelley MJ, Acott TS. Extracellular matrix gene alternative splicing by trabecular meshwork cells in response to mechanical stretching. Invest Ophthalmol Vis Sci 2007; 48:1164-1172. (Pubitemid 351261411)
71. Tumminia SJ, Mitton KP, Arora J, et al. Mechanical stretch alters the actin cytoskeletal network and signal transduction in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1998; 39:1361-1371. (Pubitemid 28307361)
72. Ramos RF, Sumida GM, Stamer WD. Cyclic mechanical stress and trabecular meshwork cell contractility. Invest Ophthalmol Vis Sci 2009; 50:3826-3832.
73. Fuchshofer R, Tamm ER. Modulation of extracellular matrix turnover in the trabecular meshwork. Exp Eye Res 2009; 88:683-688.
74. Keller KE, Bradley JM, Acott TS. Differential effects of ADAMTSs -1, -4, and - 5 in the trabecular meshwork. Invest Ophthalmol Vis Sci 2009; 50:5769-5777.
75. Baetz NW, Hoffman EA, Yool AJ, Stamer WD. Role of aquaporin-1 in trabecular meshwork cell homeostasis during mechanical strain. Exp Eye Res 2009; 89:95-100.
76. Liton PB, Luna C, Bodman M, et al. Induction of IL-6 expression by mechanical stress in the trabecular meshwork. Biochem Biophys Res Commun 2005; 337:1229-1236. (Pubitemid 41505255)
77. Luna C, Li G, Qiu J, et al. MicroRNA-24 regulates the processing of latent TGFbeta1 during cyclic mechanical stress in human trabecular meshwork cells through direct targeting of FURIN. J Cell Physiol 2011; 226:1407-1414.
78. WuDunn D. Mechanobiology of trabecular meshwork cells. Exp Eye Res 2009; 88:718-723.
79. Zhang M, Maddala R, Rao PV. Novel molecular insights into RhoA GTPaseinduced resistance to aqueous humor outflow through the trabecular meshwork. Am J Physiol Cell Physiol 2008; 295:C1057-C1070. (Pubitemid 352790316)
80. Faralli JA, Newman JR, Sheibani N, et al. Integrin-linked kinase regulates integrin signaling in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2011; 52:1684-1692.
81. Schwinn MK, Gonzalez JM Jr, Gabelt BT, et al. Heparin II domain of fibronectin mediates contractility through an alpha4beta1 co-signaling pathway. Exp Cell Res 2010; 316:1500-1512.
82. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 2001; 42:1029-1037. (Pubitemid 32289800)
83. Kaufman PL, Erickson KA, Cytochalasin B. D dose-outflow facility response relationships in the cynomolgus monkey. Invest Ophthalmol Vis Sci 1982; 23:646-650. (Pubitemid 13236102)
84. Epstein DL, Rowlette LL, Roberts BC. Acto-myosin drug effects and aqueous outflow function. Invest Ophthalmol Vis Sci 1999; 40:74-81. (Pubitemid 29029574)
85. Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol 2011; 5:667-677.
86. Lee AJ, Goldberg I. Emerging drugs for ocular hypertension. Expert Opin Emerg Drugs 2011; 16:137-161.
87. Williams RD, et al. Ocular hypotensive effect of the Rho kinase inhibitor AR- 12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 2011; 152:834.e1-841.e1.
88. Filla MS, Schwinn MK, Nosie AK, et al. Dexamethasone-associated crosslinked actin network formation in human trabecular meshwork cells involves beta3 integrin signaling. Invest Ophthalmol Vis Sci 2011; 52:2952-2959.
89. O'Reilly S, Pollock N, Currie L, et al. Inducers of cross-linked actin networks in trabecular meshwork cells. Invest Ophthalmol Vis Sci 2011; 52:7316-7324.
90. Filla MS, Woods A, Kaufman PL, Peters DM. Beta1 and beta3 integrins cooperate to induce syndecan-4-containing cross-linked actin networks in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2006; 47:1956-1967. (Pubitemid 46768276)
91. Clark AF, Brotchie D, Read AT, et al. Dexamethasone alters F-actin architecture and promotes cross-linked actin network formation in human trabecular meshwork tissue. Cell Motil Cytoskeleton 2005; 60:83-95. (Pubitemid 40165322)
92. Clark AF, Wilson K, McCartney MD, et al. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Investigative Ophthalmology Visual Science 1994; 35:281-294. (Pubitemid 24046852)
93. Pattabiraman PP, Rao PV. Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells. Am J Physiol Cell Physiol 2010; 298:C749-C763.
94. VanderWyst SS, Perkumas KM, Read AT, et al. Structural basement membrane components and corresponding integrins in Schlemm's canal endothelia. Mol Vis 2011; 17:199-209.
95. Gonzalez JM Jr, Faralli JA, Peters JM, et al. Effect of heparin II domain of fibronectin on actin cytoskeleton and adherens junctions in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2006; 47:2924-2931. (Pubitemid 351639768)
96. Keller KE, Bradley JM, Kelley MJ, Acott TS. Effects of modifiers of glycosaminoglycan biosynthesis on outflow facillity in perfusion culture. Invest Ophthalmol Vis Sci 2008; 49:2495-2505.
97. Keller KE, Bradley JM, Vranka JA, Acott TS. Segmental versican expression in the trabecular meshwork and involvement in outflow facility. Invest Ophthalmol Vis Sci 2011; 52:5049-5057.
98. Hann CR, Bahler CK, Johnson DH. Cationic ferritin and segmental flow through the trabecular meshwork. Invest Ophthalmol Vis Sci 2005; 46:1-7. (Pubitemid 40041170)
99. Hann CR, Fautsch MP. Preferential fluid flow in the human trabecular meshwork near collector channels. Invest Ophthalmol Vis Sci 2009; 50:1692-1697.
100. Buller C, Johnson D. Segmental variability of the trabecular meshwork in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 1994; 35:3841-3851. (Pubitemid 24334541)
101. Last JA, Pan T, Ding Y, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. InvestOphthalmol Vis Sci 2011; 52:2147-2152.
102. Johnson DH Does pigmentation affect the trabecular meshwork? Arch Ophthalmol 1989; 107:250-254 (Pubitemid 19055346)
103. Liton PB, Gonzalez P, Epstein DL. The role of proteolytic cellular systems in trabecular meshwork homeostasis. Exp Eye Res 2009; 88:724-728.
104. Joe MK, Tomarev SI. Expression of myocilin mutants sensitizes cells to oxidative stress-induced apoptosis: implication for glaucoma pathogenesis. Am J Pathol 2010; 176:2880-2890.
105. Izzotti A, Sacca SC, Longobardi M, Cartiglia C. Mitochondrial damage in the trabecular meshwork of patients with glaucoma. Arch Ophthalmol 2010; 128:724-730.
106. Lin Y, Epstein DL, Liton PB. Intralysosomal iron induces lysosomal membrane permeabilization and cathepsin D-mediated cell death in trabecular meshwork cells exposed to oxidative stress. Invest Ophthalmol Vis Sci 2010; 51:6483-6495.
107. Chen M, Liu B, Gao Q, et al. Mitochondria-targeted peptide MTP-131 alleviates mitochondrial dysfunction and oxidative damage in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2011; 52:7027-7037.
108. Luna C, Li G, Liton PB, et al. Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem Toxicol 2009; 47:198-204.